Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study
Methods: In this retrospective study, we enrolled 77 patients (age 52±20 years; 44.2% males) with laboratory-confirmed COVID-19 admitted to Beijing YouAn Hospital between January 21 and February 8, 2020. Epidemiological, clinical, and radiological data on admission were collected; complications and outcomes were followed up until February 26, 2020. The end point of the study was discharge alive within 2 weeks. Cox proportional-hazards regression was performed to identify risk factors for longer hospitalization.
Results: Of 77 patients, there were 34 males (44.2%), 24 (31.2%) with comorbidities, 22 (28.6%) with lymphopenia, 20 (26.0%) with severe COVID-19, and 28 (36.4%) with complications. By the end of follow-up, 64 patients (83.1%) were discharged home, eight remained in hospital, and five had died. Thirty-six patients (46.8%) were discharged within 14 days and thus reached the study end point, including 34 of the 57 patients with nonsevere COVID-19 (59.6%) and two of the 20 patients with severe COVID-19 (10%). The overall cumulative probability of the end point was 48.3%. Hospital length of stay and the duration from exposure to discharge for the 64 discharged patients were 13 (10‐16.5) days and 23 (18‐24.5) days, respectively. A multivariable stepwise Cox regression model showed that bilateral pneumonia on CT scan, shorter time from illness onset to admission, severity of disease, and lymphopenia were independently associated with longer hospitalization.
Conclusions: COVID-19 has a shorter duration of disease and hospital length of stay than severe acute respiratory syndrome. Bilateral pneumonia on CT scan, shorter period from illness onset to admission, lymphopenia, and severity of disease are the risk factors for longer hospitalization of patients with COVID-19.
Document Type: Research Article
Affiliations: 1: Department of Obstetrics, Beijing YouAn Hospital, Capital Medical University, 100069 Beijing, China 2: Hangzhou Dianzi University, Hangzhou, 310018 Zhejiang, China 3: Medical Examination Center, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 Zhejiang, China 4: Department of Infection Diseases, Beijing YouAn Hospital, Capital Medical University, 100069 Beijing, China 5: Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, 200072 Shanghai, China
Publication date: September 1, 2021
Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. Cardiovascular Innovations and Applications is the official journal of the Great Wall International Congress of Cardiology (GW-ICC). It aims to continue the work of the GW-ICC by providing a global scientific communication platform for cardiologists that bridges East and West.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites